Molecular genetics of suicide
Abstract
Background: Suicide is a complex phenomenon that is triggered by environmental factors, and probably partially also by genetic code. Genetic studies performed on suicide brain contributed interesting findings on serotonergic, dopaminergic and noradrenergic neurotransmitter systems and on cholesterol system as well as on cell morphology of the brain.
Conclusions: Despite numerous results from studies on particular subpopulations (particular psychiatric diseases, gender, etc.) supporting or rejecting association of polymorphisms and suicide, the complexity of suicidal genetics, as in most of the behavioral traits, seems to result as a consequence of more complicated undisclosed mechanisms of interactions of a larger number of genes.
Downloads
References
Bertolote JM, Fleischmann A. Suicidal behavior prevention: WHO perspectives on research. Am J Med Genet C Semin Med Genet 2005; 133: 8–12.
Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry 2006; 11: 336–51.
Marusic A, Roskar, S. Slovenija s samomorom ali brez (Slovenia with or without suicide). 1st edition. Ljubljana: DZS; 2003.
Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 1976; 33: 1193–7.
Arango V, Huang YY, Underwood MD, Mann JJ. Genetics of the serotonergic system in suicidal behavior. J Psychiatr Res 2003; 37: 375–86.
Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry 2004; 56: 581–6.
Lin PY, Tsai G. Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis. Biol Psychiatry 2004; 55: 1023–30.
Hranilovic D, Stefulj J, Furac I, Kubat M, Balija M, Jernej B. Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphisms in Croatian suicide victims. Biol Psychiatry 2003; 54: 884–9.
Frazer A, Hensler JG. Serotonin. In: George JS, Agranoff BW, Albers RW, Fisher SK, Uhler MD, eds. Basic Neurochemistry: Molecular, Cellular and Medicinal Aspects. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 1999. p. 264–90.
Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003; 23: 8788–99.
Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 1995; 688: 121–33.
Sun HF, Chang YT, Fann CS, Chang CJ, Chen YH, Hsu YP, et al. Association study of novel human serotonin 5-HT(1B) polymorphisms with alcohol dependence in Taiwanese Han Biol Psychiatry 2002; 51: 896–901.
Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in post-mortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999; 156: 1456–8.
Pungercic G, Videtic A, Pestotnik A, Pajnic IZ, Zupanc T, Balazic J, et al. Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphisms: a study on Slovenian population of suicide victims. Psychiatr Genet 2006; 16: 187–91.
Videtic A, Pungercic G, Pajnic IZ, Zupanc T, Balazic J, Tomori M, et al. Association study of seven polymorphisms in four serotonin receptor genes on suicide victims. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 669–72.
Lalovic A, Sequeira A, De Guzman R, Chawky N, Lesage A, Seguin M, et al. Investigation of completed suicide and genes involved in cholesterol metabolism. J Affect Disord 2004; 79: 25–32.
Pitchot W, Hansenne M, Ansseau M. Role of dopamine in nondepressed patients with a history of suicide attempts. Eur Psychiatry 2001; 16: 424–7.
Zalsman G, Frisch A, Lewis R, Michaelovsky E, Hermesh H, Sher L, et al. DRD4 receptor gene exon III polymorphism in inpatient suicidal adolescents. J Neural Transm 2004; 111: 1593–603.
Baumann B, Danos P, Diekmann S, Krell D, Bielau H, Geretsegger C, et al. Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. Eur Arch Psychiatry Clin Neurosci 1999; 249: 212–9.
Persson ML, Wasserman D, Geijer T, Jonsson EG, Terenius L. Tyrosine hydroxylase allelic distribution in suicide attempters. Psychiatry Res 1997; 72: 73–80.
Ono H, Shirakawa O, Nishiguchi N, Nishimura A, Nushida H, Ueno Y, et al. No evidence of an association between a functional monoamine oxidase a gene polymorphism and completed suicides. Am J Med Genet 2002; 114: 340–2.
Russ MJ, Lachman HM, Kashdan T, Saito T, Bajmakovic-Kacila S. Analysis of catechol-O-methyltransferase and 5-hydroxytryptamine transporter polymorphisms in patients at risk for suicide. Psychiatry Res 2000; 93: 73–8.
Sequeira A, Mamdani F, Lalovic A, Anguelova M, Lesage A, Seguin M, et al. Alpha 2A adrenergic receptor gene and suicide. Psychiatry Res 2004; 125: 87–93.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
